Sales & Marketing News | pharmaphorum

News

Novartis hits back at Entresto selection on Medicare list

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,

News

First 10 drugs subject to Medicare negotiations named

The identity of the first 10 medicines that will be subject to the first round of Medicare pricing negotiations has been revealed and, as expected, some big brands are in

News

GB first to approve Roche's subcutaneous Tecentriq

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

Pfizer's tornado-hit plant will soon restart production

Pfizer has confirmed that its Rocky Mount facility in North Carolina, hit by a tornado in July, will be back in operation later this year.

News

FTC hold raises hope of Amgen/Horizon deal progress

The Federal Trade Commission (FTC) in the US has paused its legal challenge to Amgen's proposed acquisition of Horizon Therapeutics, setting up settlement talks that may g

Novartis hits back at Entresto selection on Medicare list

First 10 drugs subject to Medicare negotiations named

GB first to approve Roche's subcutaneous Tecentriq

BMS grabs key approval for Reblozyl in MDS

Pfizer's tornado-hit plant will soon restart production

FTC hold raises hope of Amgen/Horizon deal progress

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks